Objective To evaluate the effect of 25G vitrectomy combined with intravitreal injection of Ranibizumab for the treatment of macular edema. Methods The data of 120 eyes of 120 patients from Jan. 2013 to Sep. 2017 were analyzed retrospectively. The patients were divided randomly into 2 groups. The control group, 60 patients, underwent 25G vitrectomy, and the observation group, 60 cases, received 25G vitrectomy after Ranibizumab intravitreal injection. The efficacy of two groups were observed. Results The difference of visual acuity before operation was not statistically significant (t=0. 073, P=0. 943), at 1, 2 weeks, 1 and 3 months after operation, the difference of visual acuity were statistically significant ( F =55. 420, P=0. 000) between the two groups. The difference of retinal thickness of macular before operation was not statistically significant (t=1. 297, P=0. 211). At 1, 2 weeks, 1 and 3 months after operation, the difference were statistically significant between the two groups (F=153. 634, P=0. 000). Operation time were (44. 20 ± 6. 44) min in the observation group, and (62. 44 ± 8. 87) min in the control group. The difference was statistically significant between the two groups (t=4. 900, P=0. 000). The difference of intraoperative bleeding was statistically significant between the two groups (χ2 =4. 236, P =0. 040). Conclusion The treatment of 25G vitrectomy combined with Ranibizumab intravitreal injection before operation for macular edema, can improve visual acuity fastly, regresse of macular edema rapidly and reduce of intraoperative operating time and complications.
Journal of Injuries and Occupational Diseases of the Eye with Ophthalmic Surgeries